<DOC>
	<DOC>NCT00042497</DOC>
	<brief_summary>The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma</brief_summary>
	<brief_title>Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients with Stage IV metastatic melanoma with 01 prior treatments for metastatic disease. All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35. Patients must have adequate organ function and an estimated life expectancy of at least 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
</DOC>